NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Roche's Ventana ALK (D5F3) CDx to identify best responders to Novartis' non-small cell lung cancer drug Zykadia (ceritinib).
Registering provides access to this and other free content.
Already have an account?Login Now.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.